Company Overview and News
Tando Resources Ltd's (ASX:TNO) Quartz Bore Project is adjacent to new discoveries in the Pilbara by De Grey Mining Ltd (ASX:DEG), Venturex Resources Ltd (ASX:VXR) and DGO Gold Ltd (ASX:DGO).
Venturex Resources Ltd (ASX:VRX) is a front-runner in leveraging itself to the silica sand sector, following the prediction of an Asian supply deficit in the near-term.
Kalamazoo Resources Ltd (ASX:KZR) has exited a trading halt with a bang this morning, with its shares jumping 121% to $0.155 with four million changing hands.
Venturex Resources Ltd's (ASX:VRX) shares have jumped 19% to $0.019 in the first hour of trade, while also being the most active stock on the ASX with 44 million changing hands.
Venturex Resources (ASX:VXR) is preparing to outlined details of a Value Engineering Study on the Sulphur Springs copper-zinc project, which is located south-east of Port Hedland in Western Australia.
The company’s shares were last trading at $0.009, up 12.5% intraday. This three-hole program is designed to test the down-plunge extensions of the known high grade zinc and copper mineralisation at Salt Creek. The targets being tested were identified from the processing of a historical geophysical dataset, combined with the development of an updated structural model. Venturex intersected 45 metres of visual stringer copper sulphides from 455 metres down-hole.
Venturex Resources Ltd (ASX:VXR) will soon commence a major drill program at its Whim Creek Zinc‐Copper Project, located 115 kilometres south‐west of Port Hedland in Western Australia. The drilling Whim Creek is expected to continue for the rest of the year with the objective of growing the existing resource of 131,300 tonnes of zinc and 87,700 tonnes of copper. The Whim Creek Project includes the Whim Creek, Mons Cupri, Salt Creek and Evelyn deposits plus 18,500 hectares of tenements covering the highly prospective Whim Creek basin.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...